APA (7th ed.) Citation

AB, G., AB, L., M, S. J., A, I. R., N, M., J, C. M., . . . I, F. (2026). Rimegepant for migraine prevention in clinical practice: A multicenter study including patients with prior anti-CGRP monoclonal antibody failure (GEMA project). Cephalalgia : an international journal of headache, 46(7), 3331024261462836. https://doi.org/10.1177/03331024261462836

Chicago Style (17th ed.) Citation

AB, Gago-Veiga, et al. "Rimegepant for Migraine Prevention in Clinical Practice: A Multicenter Study Including Patients with Prior Anti-CGRP Monoclonal Antibody Failure (GEMA Project)." Cephalalgia : An International Journal of Headache 46, no. 7 (2026): 3331024261462836. https://doi.org/10.1177/03331024261462836.

MLA (9th ed.) Citation

AB, Gago-Veiga, et al. "Rimegepant for Migraine Prevention in Clinical Practice: A Multicenter Study Including Patients with Prior Anti-CGRP Monoclonal Antibody Failure (GEMA Project)." Cephalalgia : An International Journal of Headache, vol. 46, no. 7, 2026, p. 3331024261462836, https://doi.org/10.1177/03331024261462836.